Levels of absolute survival benefit for systemic therapies of advanced cancer: A call for standards

European Journal of Cancer

Volumn 39, Issue 9, 2003, Pages 1194-1198

  Ioannidis, J P A ^a,b   Pavlidis, N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Advanced stage; Cancer; Chemotherapy; Guidelines; Meta analysis; Randomised controlled trials; Survival

Indexed keywords

ALPHA INTERFERON; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GONADORELIN AGONIST; HYDROXYUREA; IDARUBICIN; IRINOTECAN; MELPHALAN; METHOTREXATE; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; RALTITREXED; RITUXIMAB; STEROID; TAMOXIFEN; TRASTUZUMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CARCINOMA; GLIOMA; HEALTH CARE POLICY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDICAL INFORMATION; META ANALYSIS; MULTIPLE MYELOMA; OVARY CARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0037565314     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00119-9     Document Type: Review

References (41)

1. Bailar J.C. 3rd, Gornik H.L. Cancer undefeated. N. Engl. J. Med. 336:1997;1569-1574.
2. Ioannidis J.P., Lau J. Uncontrolled pearls, controlled evidence, meta-analysis and the individual patient. J. Clin. Epidemiol. 51:1998;709-711.
3. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330:1994;1029-1035.
4. Hennekens C.H., Buring J.E., Manson J.E.et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:1996;1145-1149.
5. Pignon J.P., Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol. 2:2001;475-482.
6. United States Department of Health and Human Services. Agency for Health Care Policy and Research. Acute Pain Management: Operative or Medical Procedures and Trauma. Rockville, MD, AHCPR, 1993, 107 [Clinical practice guideline No 1, AHCPR publication No 9200023].
7. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br. J. Haematol. 103:1998;100-109.
8. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16:1998;301-308.
9. Stewart L.A. Chemotherapy in adult high-grade glioma. a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet. 359:2002;1011-1018.
10. Ioannidis J.P., Lau J. The impact of high-risk patients on the results of clinical trials. J. Clin. Epidemiol. 50:1997;1089-1098.
11. Ioannidis J.P., Lau J. Completeness of safety reporting in randomized trials. an evaluation of 7 medical areas JAMA. 285:2001;437-443.
12. Harbour R., Miller J. A new system for grading recommendations in evidence based guidelines. Br. Med. J. 323:2001;334-336.
13. Canellos G.P., Anderson J.R., Propert K.J.et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med. 327:1992;1478-1484.
14. Einhorn L.H., Williams S.D., Troner M., Birch R., Greco F.A. The role of maintenance therapy in disseminated testicular cancer. N. Engl. J. Med. 305:1981;727-731.
15. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br. J. Haematol. 103:1998;100-109.
16. Klijn J.G., Blamey R.W., Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer. a meta-analysis of four randomized trials J. Clin. Oncol. 19:2001;343-353.
17. Chemotherapeutic options in chronic lymphocytic leukemia. a meta-analysis of the randomized trials J. Natl. Cancer Inst. 91:1999;861-868.
18. Interferon alfa versus chemotherapy for chronic myeloid leukemia. a meta-analysis of seven randomized trials J. Natl. Cancer Inst. 89:1997;1616-1620.
19. Hydroxyurea versus busulphan for chronic myeloid leukaemia. an individual patient data meta-analysis of three randomized trials Br. J. Haematol. 110:2000;573-576.
20. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. evidence in terms of response rate J. Clin. Oncol. 10:1992;896-903.
21. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16:1998;301-308.
22. Palliative chemotherapy for advanced colorectal cancer. systematic review and meta-analysis Br. Med. J. 321:2000;531-535.
23. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol. 12:1994;960-969.
24. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J. Natl. Cancer Inst. 88:1996;252-258.
25. Stewart L.A. Chemotherapy in adult high-grade glioma. a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet. 359:2002;1011-1018.
26. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001, 113, 1020-1034.
27. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998, 16, 3832-3842.
28. Chemotherapy in non-small cell lung cancer. a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br. Med. J. 311:1995;899-909.
29. Chemotherapy in advanced ovarian cancer. an overview of randomised clinical trials Br. Med. J. 303:1991;884-893.
30. Aabo K., Adams M., Adnitt P.et al. Chemotherapy in advanced ovarian cancer. four systematic meta-analyses of individual patient data from 37 randomized trials Br. J. Cancer. 78:1998;1479-1487.
31. Maximum androgen blockade in advanced prostate cancer. an overview of the randomised trials Lancet. 355:2000;1491-1498.
32. Stadtmauer E.A., O'Neill A., Goldstein L.J.et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N. Engl. J. Med. 342:2000;1069-1076.
33. Slamon D.J., Leyland-Jones B., Shakset al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
34. Rai K.R., Peterson B.L., Appelbaum F.R.et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343:2000;1750-1757.
35. Saltz L.B., Cox J.V., Blanke C.et al. Irinotecan plus fluorouracil and leukovorin for metastatic colorectal cancer. N. Engl. J. Med. 343:2000;905-914.
36. Maughan T.S., James R.D., Kerr D.J.et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer. a multicentre randomised trial Lancet. 359:2002;1555-1563.
37. Douillard J.Y., Cunningham D., Roth A.D.et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first treatment for metastatic colorectal cancer. a multicentre randomised trial Lancet. 355:2000;1041-1047.
38. Coiffier B., Lepage E., Briere J.et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:2002;235-242.
39. Georgoulias V., Papadakis E., Alexopoulos A.et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer. a randomised multicentre trial Lancet. 357:2001;1478-1484.
40. Schiller J.H., Harrington D., Belani C.P.et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:2002;92-98.
41. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer. the ICON3 randomised trial Lancet. 360:2002;505-515.